Sofia M.J. (Ed.) HCV: The Journey from Discovery to a Cure. Volume I

Springer, 2019. — 457 p. — (Topics in Medicinal Chemistry 31). — ISBN: 978-3-030-28206-6.Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide.
This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".From B to Non-B to C: The Hepatitis C Virus in Historical Perspective
The Discovery of the Hepatitis C Virus
HCV Molecular Virology and Animal Models
The Hepatitis C Virus Replicon System and Its Role in Drug Development
The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection
Evolution of HCV NS5B Nucleoside and Nucleotide Inhibitors
The Discovery of Sofosbuvir: A Liver-Targeted Nucleotide Prodrug for the Treatment and Cure of HCV
Evolution of HCV NS5B Non-nucleoside Inhibitors
Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase
Evolution of HCV NS3/4a Protease Inhibitors
Development and Marketing of INCIVEK (Telaprevir; VX-950): A First-Generation HCV Protease Inhibitor, in Combination with PEGylated Interferon and Ribavirin
Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections
The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)
The Invention of Grazoprevir: An HCV NS3/4a Protease Inhibitor
The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir
Discovery and Development of the Next-Generation HCV NS3 Protease Inhibitor Glecaprevir
Discovery of Voxilaprevir (GS-9857): The Pan-Genotypic Hepatitis C Virus NS3/4A Protease Inhibitor Utilized as a Component of Vosevi